Pharvaris (NASDAQ:PHVS) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Pharvaris (NASDAQ:PHVS) in a research report released on Tuesday,Benzinga reports. HC Wainwright currently has a $60.00 price target on the stock.

A number of other equities research analysts have also recently commented on PHVS. Morgan Stanley upped their target price on shares of Pharvaris from $37.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, December 4th. Wall Street Zen downgraded Pharvaris from a “hold” rating to a “sell” rating in a research note on Saturday. Oppenheimer lifted their target price on Pharvaris from $44.00 to $50.00 and gave the company an “outperform” rating in a research note on Thursday, December 4th. Leerink Partners set a $38.00 target price on Pharvaris in a report on Wednesday, December 3rd. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Pharvaris in a report on Wednesday, November 19th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $40.56.

Pharvaris Price Performance

Shares of NASDAQ PHVS opened at $26.77 on Tuesday. The business has a 50-day moving average price of $26.72 and a 200 day moving average price of $24.82. Pharvaris has a 52-week low of $11.51 and a 52-week high of $29.80.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new position in shares of Pharvaris in the 2nd quarter valued at about $57,000. Geode Capital Management LLC increased its holdings in Pharvaris by 41.1% in the second quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after buying an additional 15,769 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after acquiring an additional 783 shares during the period. Legal & General Group Plc raised its holdings in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after purchasing an additional 1,695 shares during the last quarter. Finally, Amundi boosted its position in shares of Pharvaris by 2,741,600.0% in the 2nd quarter. Amundi now owns 27,417 shares of the company’s stock worth $489,000 after buying an additional 27,416 shares in the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.